Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Download PDF Copy

Reviewed

Oct 12 2011Furiex Pharmaceuticals, Inc.

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2. These include recent presentations at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the American College of Clinical Pharmacology (ACCP) and upcoming presentations at the Infectious Diseases Society of America (IDSA) annual meeting.

Several research papers covering clinical trial and microbiology results for JNJ-Q2 have also recently been published in peer review journals, with others having been accepted for publication. The microbiology studies demonstrate JNJ-Q2's potent activity against a variety of diverse, clinically important gram positive and gram negative pathogens, including those resistant to other fluoroquinolones. Pharmacology studies demonstrate JNJ-Q2 has favorable intravenous and oral pharmacokinetic profiles. Results of the Phase II clinical study demonstrated that JNJ-Q2 is statistically non-inferior to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI).

Citations for JNJ-Q2 publications are listed below. Copies of abstracts and certain publications can be obtained at www.furiex.com.

"JNJ-Q2, a New Fluoroquinolone with Potent In Vitro Activity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains." Antimicrobial Agents and Chemotherapy, July 2011, Vol. 55, No. 7, p. 3631-3634 (D.J. Farrell, et al.)
"Determination of Disk Diffusion and MIC Quality Control Guidelines for JNJ-Q2, a Novel Quinolone." Journal of Clinical Microbiology, August 2011, Vol. 49, No. 8, p. 3009-3011 (J. E. Ross, et al.)
"Surveillance of JNJ-Q2 Activity Tested Against Staphylococcus aureus and Beta-Hemolytic Streptococci as a Component of the 2010 Sentry Antimicrobial Surveillance Program." In press at Diagnostic Microbiology and Infectious Disease (D.J. Farrell, et al.)
"Studies of the Efficacy of a New Fluoroquinolone, JNJ-Q2, in Skin, Respiratory, and Systemic Murine Models of Staphylococcus aureus and Streptococcus Pneumoniae Infection." Published online ahead of print in Antimicrobial Agents and Chemotherapy (J. Fernandez et al., 12 September 2011) http://aac.asm.org/cgi/reprint/AAC.00471-11v1.pdf
"Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2." Published online ahead of print in Antimicrobial Agents and Chemotherapy (B.J. Morrow et al, 12 September 2011)
"Evaluation of Single and Repeat Dose Pharmacokinetics, Accumulation, Absolute Bioavailability and Safety of JNJ-Q2." American College of Clinical Pharmacology, Abstract, 2011 (J. M. Davenport, et al.)
"Activity of JNJ-Q2, a New Fluoroquinolone, Tested Against Contemporary Pathogens Relevant to Acute Bacterial Skin and Skin Structure Infection (ABSSSI)." Abstract, ICAAC 2011, C2-1794 (D.J. Farrell, et al.)
"Activity of JNJ-Q2, a New Fluoroquinolone, Tested Against Contemporary Pathogens Isolated from Patients with Community-Acquired Bacterial Pneumonia (CABP)." Abstract, ICAAC 2011, C2-1795 (D.J. Farrell, et al.)
"A Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, A Novel Fluoroquinolone, Compared With Linezolid (Zyvox®) for the Treatment of Acute Bacterial Skin and Skin Structure Infection." Published online ahead of printing in Antimicrobial Agents and Chemotherapy (P.S. Covington, et al., 26 September 2011) http://aac.asm.org/cgi/reprint/AAC.05044-11v1
"Activity of JNJ-Q2, a Novel Fluoroquinolone, Tested Against Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Strains." Abstract, IDSA 2011 (D.J. Farrell, et al.)
"Activity of JNJ-Q2 and Comparators against Genetically Defined MRSA Clones." Abstract, IDSA 2011 (D.J. Farrell, et al.)